Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 7,063 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Terminated Phase 1 Interventional

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Enrolling by invitation Not applicable Interventional

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

NCT00102544
View directory record Official record
Conditions
Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma, Von Hippel Lindau Disease
Interventions
EM Tracking
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 120 Years
Enrollment
3,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

NCT07217171
View directory record Official record
Conditions
Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer, Penile Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Vaginal Squamous Cell Carcinoma, Urethral Squamous Cell Carcinoma
Interventions
EVOLVE104
Drug
Lead sponsor
EvolveImmune United, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer

NCT01114230
View directory record Official record
Conditions
Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F
Interventions
AGS-16M8F
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 4 Interventional

A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

NCT07734636
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Early RASi restart strategy, Usual Care
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer

NCT00743236
View directory record Official record
Conditions
Kidney Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Perioperative/Postoperative Complications, Urinary Complications
Interventions
cold ischemia procedure, warm ischemia procedure
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT02591199
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo, Lidocaine, Heparin
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Escondido, California • San Diego, California • Cartersville, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

ATLAS: Ambulatory Treatments for Leakage Associated With Stress

NCT00270998
View directory record Official record
Conditions
Stress Urinary Incontinence, Urinary Incontinence
Interventions
Behavioral Therapy, Intravaginal Pessary, Pessary combined with behavioral therapy
Behavioral · Device
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Maywood, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

NCT04871529
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Completed No phase listed Observational

Procalcitonin and Brain Natriuretic Peptides in Patients With Chronic Kidney Disease.

NCT03698877
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests
Diagnostic Test
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional Results available

An Effectiveness-Implementation Trial of SPIRIT in ESRD

NCT03138564
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
SPIRIT, Comparison Condition
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
39
States / cities
Atlanta, Georgia • Decatur, Georgia • North Decatur, Georgia + 29 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

NCT02230202
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Flow-mediated dilation, single blood draw
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Vaginal Estradiol Use in Pessary Care

NCT05458375
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina, Vaginal Atrophy
Interventions
Estradiol vaginal cream
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

NCT01164228
View directory record Official record
Conditions
Kidney Cancer
Interventions
Gemcitabine, Sunitinib
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
99
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Stanford, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Withdrawn Phase 2 Interventional

Prevention and Treatment of Hemodialysis Vascular Access Malfunction

NCT00179192
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
angioplasty, surgery
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 22, 2026, 10:02 AM EDT
Completed No phase listed Observational

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

NCT02203136
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tissue Biopsy, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Effect of KarXT on Urological Safety

NCT07221877
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline/trospium chloride
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Bellflower, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

NCT02739100
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

NCT06937307
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Interventions
Droxidopa capsules, Placebo
Drug · Other
Lead sponsor
Giuseppe Cullaro, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

NCT00082914
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
denileukin diftitox
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 22, 2026, 10:02 AM EDT
Completed No phase listed Observational Results available

Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS Products

NCT00388947
View directory record Official record
Conditions
Vaginal Prolapse
Interventions
AMS Prolapse Product
Device
Lead sponsor
ASTORA Women's Health
Industry
Eligibility
21 Years and older · Female only
Enrollment
1,543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Whitinsville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Combined Treatment for Mixed Incontinence

NCT01959347
View directory record Official record
Conditions
Urinary Incontinence, Stress, Urinary Incontinence, Urge
Interventions
Miduretheral Sling, Miduretheral Sling with behavioral/pelvic floor therapy
Procedure · Other
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Downey, California • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 22, 2026, 10:02 AM EDT